Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.38 |
| ▸ | CNR1 | P21554 | 12/20 | 0.36 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19177001 | 0.87 | PSMD14 (0.33) | CNR2CNR1PSMD14HSP90AA1MMP2 | |
| SCHEMBL19987518 | 0.86 | ALDH1A1 (0.32) | — | |
| SCHEMBL23502493 | 0.84 | PSMD14 (0.32) | CNR2CNR1PSMD14HSP90AA1MMP2 | |
| SCHEMBL22624130 | 0.84 | TLR8 (0.33) | PSMD14HSP90AA1MMP2MC4RRAD52 | |
| SCHEMBL20047718 | 0.83 | ALDH1A1 (0.31) | — | |
| SCHEMBL18415010 | 0.79 | BRS3 (0.38) | — | |
| SCHEMBL18737434 | 0.78 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL22023766 | 0.77 | TLR8 (0.33) | — | |
| SCHEMBL21166257 | 0.77 | KDM4E (0.49) | CNR2CNR1 | |
| SCHEMBL18852709 | 0.77 | CNR2 (0.36) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | HEPAGENE THERAPEUTICS, INC. (VG) | 2020-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | CNR2 144/4885CNR1 113/4885PSMD14 4170/4885 |
| US-20200339530-A1 | UREA DERIVATIVES AS INHIBITORS OF ASK1 | ATF1, ERN1, MAP3K1 | CNR2 4755/4885CNR1 4518/4885PSMD14 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.